Additional milestone payments upon achievement of certain development and regulatory milestones.

No definition available.

Name:	chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Additional milestone payments upon achievement of with subject to FDA approval

+ References

No definition available.

+ Details

Name:	chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents co-development, regulatory and technology transfer costs.

+ References

No definition available.

+ Details

Name:	chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of option exercise fee per program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of royalty on net sales under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of royalty on net sales for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents costs associated to a collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Initial term of agreement.

+ References

No definition available.

+ Details

Name:	chrs_InitialTermOfAgreement
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum paid amount for co-development activities.

+ References

No definition available.

+ Details

Name:	chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents upfront and milestone payments.

+ References

No definition available.

+ Details

Name:	chrs_UpfrontAndMilestonePayment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_TermSheetAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=chrs_KlingeBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborations and Other Arrangements (Details) $ / shares in Units, $ in Thousands, € in Millions			1 Months Ended	3 Months Ended				6 Months Ended			12 Months Ended
	Feb. 01, 2021 USD ($) item	Nov. 04, 2019 EUR (€)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2022 EUR (€)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)	Dec. 31, 2022 USD ($)	Apr. 14, 2020 $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions
License Agreement Fee			$ 35,000
Royalties due				$ 11,100				$ 11,100					$ 2,900
Research and development				$ 23,267		$ 41,611		$ 57,421		$ 124,528
Share Price \| $ / shares				$ 4.27				$ 4.27						$ 14.82
Finite-Lived Intangible Asset, Useful Life				10 years				10 years
Bioeq IP AG
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Initial term of agreement		10 years
Bioeq IP AG \| Licensed Products
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Maximum aggregate milestone payments \| €		€ 12.5
Additional milestone payments related to FDA approval \| €					€ 2.5
Bioeq IP AG \| Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Upfront and milestone payment											$ 11,100	€ 10.0
Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions
License Agreement Fee	$ 35,000
Collaboration Agreement \| Anti-TIGIT Antibody and IL-2 cytokine
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program			$ 170,000				$ 170,000
Junshi Biosciences
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Undisclosed preclinical \| item	2
License Agreement Fee							$ 35,000
Collaboration agreement, royalty on net sales for each exercised option, percentage	18.00%
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program	$ 85,000
Maximum paid amount for co-development activities (per licensed compound)	25,000
Research and development				$ 3,000		$ 9,900		$ 4,600		$ 60,000
Junshi Biosciences \| Accrued and other current liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Co-development, regulatory and technology transfer costs				4,600				4,600
Junshi Biosciences \| Accounts payable
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Co-development, regulatory and technology transfer costs				$ 3,100				$ 3,100
Junshi Biosciences \| Toripalimab
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid	$ 150,000
Collaboration agreement, royalty on net sales, percentage	20.00%
Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones	$ 380,000
Scenario, Plan \| Term Sheet Agreement \| Klinge Biopharma
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid \| €									€ 30.0